BlackRock Inc. purchased a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 6,256,762 shares of the medical instruments supplier's stock, valued at approximately $27,905,000. BlackRock Inc. owned 9.09% of OraSure Technologies as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of OSUR. Prudential Financial Inc. acquired a new stake in OraSure Technologies during the 2nd quarter worth about $31,000. Quadrature Capital Ltd acquired a new stake in shares of OraSure Technologies during the fourth quarter valued at approximately $28,000. Diversify Wealth Management LLC purchased a new stake in shares of OraSure Technologies in the 1st quarter valued at approximately $36,000. Amundi purchased a new stake in shares of OraSure Technologies in the 1st quarter valued at approximately $47,000. Finally, BNP Paribas Financial Markets boosted its stake in OraSure Technologies by 102.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 7,720 shares during the period. Hedge funds and other institutional investors own 93.50% of the company's stock.
OraSure Technologies Price Performance
OSUR opened at $3.61 on Thursday. The company has a market capitalization of $248.98 million, a PE ratio of -5.23 and a beta of 0.99. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $4.58. The business has a 50-day moving average of $4.01 and a 200-day moving average of $3.56.
Analysts Set New Price Targets
Several equities analysts have weighed in on the stock. Weiss Ratings upgraded shares of OraSure Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, June 4th. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a report on Monday, August 10th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Reduce" and a consensus target price of $3.00.
View Our Latest Research Report on OSUR
OraSure Technologies Profile
(
Free Report)
OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.
The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.
Further Reading
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
